Ziyad Al-Aly: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
removed Category:Washington University in St. Louis faculty using HotCat School of Medicine faculty
added couple references
Line 7: Line 7:


== Long Covid work ==
== Long Covid work ==
Al-Aly led work which provided the first systematic characterization of the post-acute sequelae of SARS-CoV-2 infection.<ref>{{Cite journal |last1=Al-Aly |first1=Ziyad |last2=Xie |first2=Yan |last3=Bowe |first3=Benjamin |date=June 2021 |title=High-dimensional characterization of post-acute sequelae of COVID-19 |url=https://www.nature.com/articles/s41586-021-03553-9 |journal=Nature |language=en |volume=594 |issue=7862 |pages=259–264 |doi=10.1038/s41586-021-03553-9 |pmid=33887749 |bibcode=2021Natur.594..259A |s2cid=233373053 |issn=1476-4687}}</ref> He subsequently led work which characterized the increased risks of cardiovascular disease,<ref>{{Cite journal |last1=Xie |first1=Yan |last2=Xu |first2=Evan |last3=Bowe |first3=Benjamin |last4=Al-Aly |first4=Ziyad |date=March 2022 |title=Long-term cardiovascular outcomes of COVID-19 |journal=Nature Medicine |language=en |volume=28 |issue=3 |pages=583–590 |doi=10.1038/s41591-022-01689-3 |pmid=35132265 |pmc=8938267 |issn=1546-170X}}</ref> neurologic disorders,<ref>{{Cite journal |last1=Xu |first1=Evan |last2=Xie |first2=Yan |last3=Al-Aly |first3=Ziyad |date=November 2022 |title=Long-term neurologic outcomes of COVID-19 |journal=Nature Medicine |language=en |volume=28 |issue=11 |pages=2406–2415 |doi=10.1038/s41591-022-02001-z |pmid=36138154 |pmc=9671811 |issn=1546-170X}}</ref> diabetes,<ref>{{Cite journal |last1=Xie |first1=Yan |last2=Al-Aly |first2=Ziyad |date=2022-05-01 |title=Risks and burdens of incident diabetes in long COVID: a cohort study |journal=The Lancet Diabetes & Endocrinology |language=English |volume=10 |issue=5 |pages=311–321 |doi=10.1016/S2213-8587(22)00044-4 |issn=2213-8587 |pmid=35325624|pmc=8937253 }}</ref> and kidney disease<ref>{{Cite journal |last1=Bowe |first1=Benjamin |last2=Xie |first2=Yan |last3=Xu |first3=Evan |last4=Al-Aly |first4=Ziyad |date=November 2021 |title=Kidney Outcomes in Long COVID |url=https://journals.lww.com/JASN/Fulltext/2021/11000/Kidney_Outcomes_in_Long_COVID.19.aspx |journal=Journal of the American Society of Nephrology |language=en-US |volume=32 |issue=11 |pages=2851 |doi=10.1681/ASN.2021060734 |pmid=34470828 |s2cid=237389462 |issn=1046-6673}}</ref> following SARS-CoV-2 infection. His lab also produced evidence characterizing the effects of vaccines on Long Covid<ref>{{Cite journal |last1=Al-Aly |first1=Ziyad |last2=Bowe |first2=Benjamin |last3=Xie |first3=Yan |date=July 2022 |title=Long COVID after breakthrough SARS-CoV-2 infection |journal=Nature Medicine |language=en |volume=28 |issue=7 |pages=1461–1467 |doi=10.1038/s41591-022-01840-0 |pmid=35614233 |pmc=9307472 |issn=1546-170X}}</ref> and the health consequences of repeated infections with SARS-CoV-2.<ref>{{Cite journal |last1=Bowe |first1=Benjamin |last2=Xie |first2=Yan |last3=Al-Aly |first3=Ziyad |date=November 2022 |title=Acute and postacute sequelae associated with SARS-CoV-2 reinfection |journal=Nature Medicine |language=en |volume=28 |issue=11 |pages=2398–2405 |doi=10.1038/s41591-022-02051-3 |pmid=36357676 |pmc=9671810 |issn=1546-170X}}</ref>
Al-Aly led work which provided the first systematic characterization of the post-acute sequelae of SARS-CoV-2 infection.<ref>{{Cite journal |last1=Al-Aly |first1=Ziyad |last2=Xie |first2=Yan |last3=Bowe |first3=Benjamin |date=June 2021 |title=High-dimensional characterization of post-acute sequelae of COVID-19 |url=https://www.nature.com/articles/s41586-021-03553-9 |journal=Nature |language=en |volume=594 |issue=7862 |pages=259–264 |doi=10.1038/s41586-021-03553-9 |pmid=33887749 |bibcode=2021Natur.594..259A |s2cid=233373053 |issn=1476-4687}}</ref> He subsequently led work which characterized the increased risks of cardiovascular disease,<ref>{{Cite journal |last1=Xie |first1=Yan |last2=Xu |first2=Evan |last3=Bowe |first3=Benjamin |last4=Al-Aly |first4=Ziyad |date=March 2022 |title=Long-term cardiovascular outcomes of COVID-19 |journal=Nature Medicine |language=en |volume=28 |issue=3 |pages=583–590 |doi=10.1038/s41591-022-01689-3 |pmid=35132265 |pmc=8938267 |issn=1546-170X}}</ref> neurologic disorders,<ref>{{Cite journal |last1=Xu |first1=Evan |last2=Xie |first2=Yan |last3=Al-Aly |first3=Ziyad |date=November 2022 |title=Long-term neurologic outcomes of COVID-19 |journal=Nature Medicine |language=en |volume=28 |issue=11 |pages=2406–2415 |doi=10.1038/s41591-022-02001-z |pmid=36138154 |pmc=9671811 |issn=1546-170X}}</ref> mental health disorders,<ref>{{Cite journal |last=Xie |first=Yan |last2=Xu |first2=Evan |last3=Al-Aly |first3=Ziyad |date=2022-02-16 |title=Risks of mental health outcomes in people with covid-19: cohort study |url=https://www.bmj.com/content/376/bmj-2021-068993 |journal=BMJ |language=en |volume=376 |pages=e068993 |doi=10.1136/bmj-2021-068993 |issn=1756-1833 |pmid=35172971}}</ref> diabetes,<ref>{{Cite journal |last1=Xie |first1=Yan |last2=Al-Aly |first2=Ziyad |date=2022-05-01 |title=Risks and burdens of incident diabetes in long COVID: a cohort study |journal=The Lancet Diabetes & Endocrinology |language=English |volume=10 |issue=5 |pages=311–321 |doi=10.1016/S2213-8587(22)00044-4 |issn=2213-8587 |pmid=35325624|pmc=8937253 }}</ref> dyslipidemia,<ref>{{Cite journal |last=Xu |first=Evan |last2=Xie |first2=Yan |last3=Al-Aly |first3=Ziyad |date=2023-02-01 |title=Risks and burdens of incident dyslipidaemia in long COVID: a cohort study |url=https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00355-2/abstract |journal=The Lancet Diabetes & Endocrinology |language=English |volume=11 |issue=2 |pages=120–128 |doi=10.1016/S2213-8587(22)00355-2 |issn=2213-8587 |pmid=36623520}}</ref> and kidney disease<ref>{{Cite journal |last1=Bowe |first1=Benjamin |last2=Xie |first2=Yan |last3=Xu |first3=Evan |last4=Al-Aly |first4=Ziyad |date=November 2021 |title=Kidney Outcomes in Long COVID |url=https://journals.lww.com/JASN/Fulltext/2021/11000/Kidney_Outcomes_in_Long_COVID.19.aspx |journal=Journal of the American Society of Nephrology |language=en-US |volume=32 |issue=11 |pages=2851 |doi=10.1681/ASN.2021060734 |pmid=34470828 |s2cid=237389462 |issn=1046-6673}}</ref> following SARS-CoV-2 infection. His lab also produced evidence characterizing the effects of COVID-19 vaccines on Long Covid<ref>{{Cite journal |last1=Al-Aly |first1=Ziyad |last2=Bowe |first2=Benjamin |last3=Xie |first3=Yan |date=July 2022 |title=Long COVID after breakthrough SARS-CoV-2 infection |journal=Nature Medicine |language=en |volume=28 |issue=7 |pages=1461–1467 |doi=10.1038/s41591-022-01840-0 |pmid=35614233 |pmc=9307472 |issn=1546-170X}}</ref> and the health consequences of repeated infections with SARS-CoV-2.<ref>{{Cite journal |last1=Bowe |first1=Benjamin |last2=Xie |first2=Yan |last3=Al-Aly |first3=Ziyad |date=November 2022 |title=Acute and postacute sequelae associated with SARS-CoV-2 reinfection |journal=Nature Medicine |language=en |volume=28 |issue=11 |pages=2398–2405 |doi=10.1038/s41591-022-02051-3 |pmid=36357676 |pmc=9671810 |issn=1546-170X}}</ref>


==References==
==References==

Revision as of 23:50, 27 January 2023

Ziyad Al-Aly is an American physician and clinical epidemiologist who is currently Director of the Clinical Epidemiology Center and Chief of the Research and Development at the Veterans Affairs St. Louis Health Care System.[1][2] He is also a clinical epidemiologist at Washington University in St. Louis[2] He has led multiple studies on long COVID and its sequelae.[3]

He holds a medical degree from the American University of Beirut.[4] He completed his post-graduate medical education at Saint Louis University and Washington University in Saint Louis.

He has an h-index of 70 according to Google Scholar.[5] Link to his publications.

Long Covid work

Al-Aly led work which provided the first systematic characterization of the post-acute sequelae of SARS-CoV-2 infection.[6] He subsequently led work which characterized the increased risks of cardiovascular disease,[7] neurologic disorders,[8] mental health disorders,[9] diabetes,[10] dyslipidemia,[11] and kidney disease[12] following SARS-CoV-2 infection. His lab also produced evidence characterizing the effects of COVID-19 vaccines on Long Covid[13] and the health consequences of repeated infections with SARS-CoV-2.[14]

References

  1. ^ "Repeat coronavirus infections can still be dangerous, study suggests". The Washington Post. Retrieved 11 November 2022.
  2. ^ a b "Ziyad Al-Aly, MD". Washington University in St. Louis. Retrieved 11 November 2022.
  3. ^ "COVID-19 infections increase risk of long-term brain problems". Washington University in St. Louis. Retrieved 11 November 2022.
  4. ^ "Ziyad Al-Aly, MD, FASN". Washington University in St. Louis. Retrieved 11 November 2022.
  5. ^ "Ziyad Al-Aly, MD". Google Scholar. Retrieved 11 November 2022.
  6. ^ Al-Aly, Ziyad; Xie, Yan; Bowe, Benjamin (June 2021). "High-dimensional characterization of post-acute sequelae of COVID-19". Nature. 594 (7862): 259–264. Bibcode:2021Natur.594..259A. doi:10.1038/s41586-021-03553-9. ISSN 1476-4687. PMID 33887749. S2CID 233373053.
  7. ^ Xie, Yan; Xu, Evan; Bowe, Benjamin; Al-Aly, Ziyad (March 2022). "Long-term cardiovascular outcomes of COVID-19". Nature Medicine. 28 (3): 583–590. doi:10.1038/s41591-022-01689-3. ISSN 1546-170X. PMC 8938267. PMID 35132265.
  8. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (November 2022). "Long-term neurologic outcomes of COVID-19". Nature Medicine. 28 (11): 2406–2415. doi:10.1038/s41591-022-02001-z. ISSN 1546-170X. PMC 9671811. PMID 36138154.
  9. ^ Xie, Yan; Xu, Evan; Al-Aly, Ziyad (2022-02-16). "Risks of mental health outcomes in people with covid-19: cohort study". BMJ. 376: e068993. doi:10.1136/bmj-2021-068993. ISSN 1756-1833. PMID 35172971.
  10. ^ Xie, Yan; Al-Aly, Ziyad (2022-05-01). "Risks and burdens of incident diabetes in long COVID: a cohort study". The Lancet Diabetes & Endocrinology. 10 (5): 311–321. doi:10.1016/S2213-8587(22)00044-4. ISSN 2213-8587. PMC 8937253. PMID 35325624.
  11. ^ Xu, Evan; Xie, Yan; Al-Aly, Ziyad (2023-02-01). "Risks and burdens of incident dyslipidaemia in long COVID: a cohort study". The Lancet Diabetes & Endocrinology. 11 (2): 120–128. doi:10.1016/S2213-8587(22)00355-2. ISSN 2213-8587. PMID 36623520.
  12. ^ Bowe, Benjamin; Xie, Yan; Xu, Evan; Al-Aly, Ziyad (November 2021). "Kidney Outcomes in Long COVID". Journal of the American Society of Nephrology. 32 (11): 2851. doi:10.1681/ASN.2021060734. ISSN 1046-6673. PMID 34470828. S2CID 237389462.
  13. ^ Al-Aly, Ziyad; Bowe, Benjamin; Xie, Yan (July 2022). "Long COVID after breakthrough SARS-CoV-2 infection". Nature Medicine. 28 (7): 1461–1467. doi:10.1038/s41591-022-01840-0. ISSN 1546-170X. PMC 9307472. PMID 35614233.
  14. ^ Bowe, Benjamin; Xie, Yan; Al-Aly, Ziyad (November 2022). "Acute and postacute sequelae associated with SARS-CoV-2 reinfection". Nature Medicine. 28 (11): 2398–2405. doi:10.1038/s41591-022-02051-3. ISSN 1546-170X. PMC 9671810. PMID 36357676.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ziyad_Al-Aly&oldid=1135967389"